CD30 ligand in lymphoma patients with CD30+ tumors

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3355-3362

  Younes, Anas ^a   Consoli, Ugo ^a   Snell, Virginia ^a   Clodi, Katharina ^a   Kliche, Kay Oliver ^a   Palmer, J Lynn ^a   Gruss, Hans J ^a   Armitage, Richard ^a   Thomas, Elaine K ^a   Cabanillas, Fernando ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 17944400431     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3355     Document Type: Article

References (24)

1. Shresta S, Heusel JW, Macivor DM, et al: Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Immunol Rev 146:211-221, 1995
2. Smyth MJ, Trapani JA: Granzymes: Exogenous proteinases that induce target cell apoptosis. Immunol Today 16:202-206, 1995
3. Gruss HJ, Dower SK: Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 85:3378-3404, 1995
4. Cosman D: A family of ligands for the TNF receptor superfamily. Stem Cells (Dayt) 12:440-455, 1994
5. Nagata S: Fas and Fas ligand: A death factor and its receptor. Adv Immunol 57:129-144, 1994
6. Nagaa S, Golstein P: The Fas death factor. Science 267:1449-1456, 1995
7. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39-43, 1995
8. Owen-Schaub LB, Angelo LS, Radinsky R, et al: Soluble Fas/ APO-1 in tumor cells: A potential regulator of apoptosis? Cancer Lett 94:1-8, 1995
9. Cheng J, Zhou T, Liu C, et al: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762, 1994
10. Smith CA, Gruss HJ, Davis T, et al: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349-1360, 1993
11. Younes A, Consoli U, Zhao S, et al: CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 93:569-571, 1996
12. Gruss HJ, Boiani N, Williams DE, et al: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83:2045-2056, 1994
13. Nadili G, Vinante F, Ambrosetti A, et al: Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 12:793-797, 1994
14. Pizzolo G, Vinante F, Chilosi M, et al: Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: Relationship with disease activity and clinical stage. Br J Haematol 75:282-284, 1990
15. Younes A, Zhao S, Jendiroba D, et al: Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma. Blood 85:2813-2816, 1995
16. Vermes I, Haanen C, Steffens-Nakken H, et al: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184:39-51, 1995
17. Haycock KA, Roth J, Gagnon J: StatView. Berkeley, CA, Abacus Concepts, Inc, 1994
18. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
19. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
20. Falini B, Pileri S, Pizzolo G, et al: CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1-14, 1995
21. Del Prete G, Maggi E, Pizzolo G, et al: CD30, Th2 cytokines and HIV infection: A complex and fascinating link. Immunol Today 16:76-80, 1995
22. Alzona M, Jack HM, Fisher RI, et al: CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol 153:2861-2867, 1994
23. Gause A, Pohl C, Tschiersch A, et al: Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 77:1983-1988, 1991
24. Josimovic-Alasevic O, Durkop H, Schwarting R, et al: Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19:157-162, 1989